Q3 2025 Allogene Therapeutics Inc Earnings Call Transcript
Key Points
- Allogene Therapeutics Inc (ALLO) is advancing its allogeneic platform, which is designed to make cell therapies scalable, practical, and potentially curative.
- The company has over 50 active sites across the US and Canada for its pivotal Alpha 3 trial, with plans to expand into Australia and South Korea.
- Allogene Therapeutics Inc (ALLO) has a strong financial foundation with $207.1 million in cash, cash equivalents, and investments, supporting a cash runway into the second half of 2027.
- The company's dagger technology has shown promising results in the Traverse trial, with durable responses in patients with metastatic kidney cancer.
- Allogene Therapeutics Inc (ALLO) is preparing for significant milestones in 2026, including pivotal interim data from the Alpha 3 trial and proof of concept from ALLO-329 in autoimmune disease.
- The company faces scientific and operational challenges, particularly in autoimmune indications, which could impact clinical development.
- Enrollment and screening processes for trials can be complex and time-consuming, potentially affecting timelines.
- The company reported a net loss of $41.4 million for the third quarter, highlighting ongoing financial challenges.
- There is uncertainty around the success of the MRD conversion in the Alpha 3 trial, which is critical for future regulatory submissions.
- Allogene Therapeutics Inc (ALLO) competes for patients in a crowded field, which may impact the pace of clinical trials and data collection.
Ladies and gentlemen, please stand by.
Your conference will begin shortly.
Please continue to stand by and thank you for your patience.
Hello and thank you for standing by.
Welcome to Allery Therapeutics, 3rd quarter, 2025 conference call.
At this time, all participants on a listen-only mode.
After the speaker's presentation, there will be a question-and-answer session.
To ask the question during the session, you would need to press star 11 on your telephone.
You would then hear automated message advising your hand is raised.
To withdraw your question, please 1st 11 again.
Please be aware that the conference call is being recorded.
I would now like to send the call over to Christine Cassiano, Chief corporate affairs, and brand strategy Officer.
Miss Kassana, please go ahead.
Thank you, operator, and welcome everyone to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
